시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
전립선암 항원 3 검사 시장 : 인사이트 및 예측(-2030년)
Global Prostate Cancer Antigen 3 Test Market Insights, Forecast to 2030
상품코드 : 1455728
리서치사 : QYResearch
발행일 : 2024년 03월
페이지 정보 : 영문
 라이선스 & 가격 (부가세 별도)
US $ 4,900 ￦ 7,270,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 등을 Copy & Paste 할 수 있습니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,350 ￦ 10,905,000
PDF (Multi User License) help
PDF, Excel 보고서를 동일 기업내 10명까지 이용하실 수 있는 라이선스입니다. 텍스트 등을 Copy & Paste 할 수 있습니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF, Excel, Word 이용 범위와 동일합니다.
US $ 9,800 ￦ 14,540,000
PDF (Enterprise User License) help
PDF, Excel, Word 보고서를 동일 기업내 모든 구성원이 이용하실 수 있는 라이선스입니다. 텍스트 등을 Copy & Paste 할 수 있습니다. 인쇄 가능하며, 인쇄물의 이용 범위는 PDF, Excel, Word 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 전립선암 항원 3 검사 시장 규모는 2023년 5,169만 달러에서 2024-2030년 연평균 9.09%의 CAGR로 2030년에는 9,364만 달러에 달할 것으로 예상됩니다.

미국 및 캐나다의 전립선암 항원 3 검사 시장은 2023년 1,910만 달러에서 예측 기간(2024-2030년) 동안 8.96%의 CAGR로 성장하여 2030년에는 3,431만 달러에 달할 것으로 예상됩니다.

중국의 전립선암 항원 3 검사 시장은 2023년 750만 달러에서 예측 기간(2024-2030년) 동안 11.03%의 CAGR로 성장하여 2030년에는 1,534만 달러에 달할 것으로 예상됩니다.

유럽의 전립선암 항원 3 검사 시장은 2023년 1,559만 달러에서 예측 기간(2024-2030년) 동안 8.20%의 CAGR로 성장하여 2030년에는 2,669만 달러에 달할 것으로 예상됩니다.

세계 전립선암 항원 3 검사 시장의 주요 업체는 Thermo Fisher Scientific, MDxHealth, Exosome Diagnostics GmbH, Creative Diagnostics, Lytech, YUBO, MicroDiag Biomedicine 등이며, 2023년 세계 상위 5개 기업의 매출 점유율은 약 82.81%였습니다.

본 보고서는 세계의 전립선암 항원 3 검사 시장에 대해 분석했으며, 유형별·용도별·지역별(국가별) 시장 동향 전망(2019-2030년), 주요 기업 개요 등을 조사하여 전해드립니다.

목차

제1장 조사 개요

제2장 세계의 성장 동향

제3장 전립선암 항원 3 검사 경쟁 상황 : 기업별

제4장 전립선암 항원 3 검사 : 종류별 내역 데이터

제5장 전립선암 항원 3 검사 : 용도별 내역 데이터

제6장 북미

제7장 유럽

제8장 중국

제9장 아시아(중국 제외)

제10장 중동 및 아프리카, 라틴아메리카

제11장 주요 기업 개요

제12장 애널리스트의 견해/결론

제13장 부록

ksm
영문 목차

영문목차

The global Prostate Cancer Antigen 3 Test market size is projected to reach US 93.64 million by 2030, from US$ 51.69 million in 2023, at a CAGR of 9.09% during 2024-2030.

The US & Canada market for Prostate Cancer Antigen 3 Test is estimated to increase from $ 19.1 million in 2023 to reach $ 34.31 million by 2030, at a CAGR of 8.96% during the forecast period of 2024 through 2030.

The China market for Prostate Cancer Antigen 3 Test is estimated to increase from $ 7.50 million in 2023 to reach $ 15.34 million by 2030, at a CAGR of 11.03% during the forecast period of 2024 through 2030.

The Europe market for Prostate Cancer Antigen 3 Test is estimated to increase from $ 15.59 million in 2023 to reach $ 26.69 million by 2030, at a CAGR of 8.20% during the forecast period of 2024 through 2030.

The global key companies of Prostate Cancer Antigen 3 Test include Hologic, Thermo Fisher Scientific, MDxHealth, Exosome Diagnostics GmbH, Creative Diagnostics, Lytech, YUBO, MicroDiag Biomedicine, etc. In 2023, the global top five players had a share approximately 82.81% in terms of revenue

Report Includes

This report presents an overview of global market for Prostate Cancer Antigen 3 Test market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Prostate Cancer Antigen 3 Test, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Prostate Cancer Antigen 3 Test, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Prostate Cancer Antigen 3 Test revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Prostate Cancer Antigen 3 Test market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Prostate Cancer Antigen 3 Test revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Hologic, Thermo Fisher Scientific, MDxHealth, Exosome Diagnostics GmbH, Creative Diagnostics, Lytech, YUBO, MicroDiag Biomedicine, and etc.

Market Segmentation

By Company

Segment by Type

Segment by Application

By Region

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Revenue of Prostate Cancer Antigen 3 Test in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Prostate Cancer Antigen 3 Test companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.

Chapter 7: Europe by Type, by Application and by country, revenue for each segment.

Chapter 8: China by Type, and by Application, revenue for each segment.

Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.

Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.

Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Antigen 3 Test revenue, gross margin, and recent development, etc.

Chapter 12: Analyst's Viewpoints/Conclusions

Table of Contents

1 Report Overview

2 Global Growth Trends

3 Competition Landscape by Key Players

4 Prostate Cancer Antigen 3 Test Breakdown Data by Type

5 Prostate Cancer Antigen 3 Test Breakdown Data by Application

6 North America

7 Europe

8 China

9 Asia (excluding China)

10 Middle East, Africa, and Latin America

11 Key Players Profiles

12 Analyst's Viewpoints/Conclusions

13 Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기